Bevacizumab, a humanized recombinant monoclonal antibody that targets vascular endothelial growth factor (VEGF), has been shown to be well tolerated and efficacious in delaying tumor progression in the treatment of recurrent malignant glioma and is FDA approved for recurrent glioblastoma [14,15,16,209]. The gene discussed is VEGFA; the disease is malignant glioma.